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Abstract
Objective
To investigate the risk of death from cardiovascular disease between patients who were and
were not prescribed antihypertensive medication following stroke or TIA.
Methods
This was a large cohort study using routinely collected prospective data from the Australian
Stroke Clinical Registry. Patients registered between 2009 and 2013 who were discharged to
the community or rehabilitation were included. Cases were linked to the National Death Index
to determine the date and cause of death. Propensity score matching with stratification was
utilized to compare between similar subgroups of patients. Multivariable competing risks
regression, with noncardiovascular death as a competing risk, was conducted to investigate the
association between the prescription of antihypertensive medications and cardiovascular death
at 180 days after admission.
Results
Among 12,198 patients from 40 hospitals, 70% were prescribed antihypertensive medications.
Patients who were older, were treated in a stroke unit, and had better socioeconomic position
were more often discharged from hospital with an antihypertensive medication. Including only
patients within propensity score quintiles with acceptable levels of balance in covariates be-
tween groups (n = 8,786), prescription of antihypertensive medications was associated with
a 23% greater reduction in the subhazard of cardiovascular death compared to those who were
not prescribed these agents (subhazard ratio 0.77; 95% confidence interval 0.61 to 0.97).
Conclusions
People who are prescribed antihypertensive medications at discharge from hospital after
a stroke or TIA demonstrate better cardiovascular and all-cause survival outcomes than those
not prescribed these agents.
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The risk of cardiovascular disease (CVD) can be reduced by
up to 31% and all-cause mortality by 13% with the use of
antihypertensive medications.1,2 The recommendation by the
American Heart Association (AHA) in 2011 that antihyper-
tensive medications should be provided to all patients “be-
yond the first 24 hours” of stroke or TIA unless
contraindicated3 was based on the results of the Perindopril
Protection Against Recurrent Stroke Study (PROGRESS)
clinical trial.4 In this trial, antihypertensive medications were
beneficial for those with high and normal blood pressure.4
More recent evidence5–7 has raised doubt on the benefit of
blood pressure lowering too early following ischemic stroke,
but not for other stroke types.8–10 Consequently, the 2014
AHA guidelines were more conservative, with recom-
mendations that antihypertensive therapy should be initiated or
resumed after “the first several days” of the stroke.11 Although
most patients are discharged from acute care several days after
stroke onset, there is now uncertainty among clinicians as to
whether or not patients should be prescribed thesemedications
prior to discharge from acute hospital care,12,13 as evidenced by
recent declines in patients with all stroke types being prescribed
these agents at discharge.14 The use of data from clinical reg-
istries can provide important population-based perspectives on
how antihypertensive therapies are incorporated into routine
clinical discharge practices.
We aimed to examine differences in the risk of death due to
CVD among patients with stroke or TIA discharged to the
community or rehabilitation between those who were and
were not prescribed antihypertensive medication.
Methods
Data sources
This was a large retrospective cohort study using routinely
collected prospective data from the Australian Stroke Clinical
Registry (AuSCR). The AuSCR is a national database designed
to monitor the quality of acute care provided to patients who
are hospitalized with stroke or TIA, excluding subarachnoid
hemorrhage. Eligible cases were identified using a clinical di-
agnosis of stroke or TIA, i.e., determined by a clinician, based
on diagnostic assessments rather than relying on ICD-10 pri-
mary discharge diagnosis codes, which are determined by ad-
ministrative coders. This method is consistent with other
national registries.16,17 See table e-1 (links.lww.com/WNL/
A192) for the specific definitions used. In situations where the
clinical diagnosis was missing or undetermined, the ICD-10
codes were used to differentiate among infarct, intracerebral
hemorrhage (ICH), or TIA (103 cases, 0.8%). Patient data
were entered into the registry prospectively by clinicians, from
participating hospitals, who were provided with a data dictio-
nary and standardized training. In-built logic checks, data
quality checks by registry staff, and medical record audits un-
dertaken by external auditors were used to ensure data quality.
Data on date and underlying cause of death were provided for
all AuSCR registrants through annual linkages with the Na-
tional Death Index (NDI), a national registry of deaths held by
the Australian Institute of Health and Welfare (specificity and
sensitivity >98% between AuSCR and death registry data for in-
hospital deaths; unpublished AuSCR data).
A nationally endorsed clinical minimum dataset, collected for
each episode of care, included clinical and demographic data
as well as information on clinical care performance measures.
The AuSCR is one of the few national stroke registries that
monitors the prescription of antihypertensive medications at
discharge.17 All registrants who are alive at discharge are
considered eligible to receive antihypertensive medications
because only a small proportion of patients (2%–3%) have
contraindications to receiving these medications (un-
published data from the Stroke Foundation14).
In the AuSCR data dictionary, antihypertensive medication is
defined as
Antihypertensive agents commonly include angiotensin converting
enzyme inhibitors (e.g., Perindopril, Ramipril) with or without diuretic
and angiotensin II receptor antagonists (e.g., Telmisartan, Losartin) with
or without diuretic. Other agents include alpha blockers (e.g., Prazosin),
beta blockers (e.g., Atenolol, Metoprolol), calcium channel blockers (e.g.,
Amlodipine, Diltiazem hydrochloride) and thiazide diuretics (refer to
Monthly Index of Medical Specialties for full list).
Patients who are continuing with previously prescribed anti-
hypertensive medications or who have been prescribed these
medications for the first time during their admission are
recorded as having been discharged on these medications.
Data coding and analysis
In this study we included adults (aged ≥18 years) with a first
episode of stroke or TIA, registered in the AuSCR database
between 2009 and 2013, who were discharged home, to res-
idential care, or to inpatient rehabilitation. This time delay
provided an allowance of up to 2 years for receiving in-
formation on the underlying cause of death for any potential
deaths within 180 days of admission. We excluded those who
experienced an in-hospital stroke (4% excluded). These
restrictions ensured that patients who may have been
Glossary
AHA = American Heart Association; AuSCR = Australian Stroke Clinical Registry; CI = confidence interval; CVD =
cardiovascular disease; ICD-10 = International Classification of Diseases–10; ICH = intracerebral hemorrhage; IRSAD = Index of
Relative Advantage and Disadvantage; NDI = National Death Index; SHR = subhazard ratio.
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transferred to end-of-life care were not included in the anal-
yses. Patients were considered not to have been prescribed an
antihypertensive medication if this indicator was coded as
“no,” “unknown,” or where a response was missing in the
database (2% of data were missing). Following these adjust-
ments, missing data were present in 4 of the covariates used
(<1% for age, sex, and stroke type and 9% for ability to walk
on admission) and were excluded from the denominators.
Socioeconomic position of registrants was derived using the
Index of Relative Advantage and Disadvantage (IRSAD)
provided by the Australian Bureau of Statistics.18 Greater
IRSAD scores indicate lesser relative disadvantage.
As our primary outcome was death due to CVD, we excluded
registrants who were known to have died within 180 days of
their stroke admission (i.e., had a recorded date of death) but
had a missing cause of death (n = 94, 11% of deaths). This was
because it was not possible to categorize them as having died
of CVD for the competing risk analysis (figure 1). Sensitivity
analyses were performed to examine the effect of this exclu-
sion on our results. In the first sensitivity analysis, the deaths
with an unknown cause were classified as being due to CVD,
and in the second, the deaths with an unknown cause were
classified as being due to a non-CVD cause.
Statistics
Mann-Whitney U tests and χ2 tests were used to assess dif-
ferences between those who were and were not prescribed
antihypertensive medications at discharge. As there may be
reasons, valid or otherwise, as to why some patients are not
prescribed antihypertensive medication, we used propensity
score matching to minimize confounding by indication.
Matching on propensity scores is commonly used in non-
randomized studies to account for differences between indi-
viduals who do and do not receive a treatment based on the
probability that they will receive the treatment.19–21
A propensity score was generated for each registrant, using
multivariable logistic regression, based on the probability of
being prescribed antihypertensive medication at discharge
(dependent variable). Eleven independent clinical and de-
mographic variables (table 1), shown to be associated with
prescription of antihypertensive medication or death at 180
days on univariable analysis, were included in the model.
Ability to walk on admission was used as a measure of stroke
severity and has been shown to be a reliable predictor of death
in large population samples.22,23 Discharge destination (cat-
egorized as home, inpatient rehabilitation, or residential care)
was also included because this is decided prior to prescription
of medications at discharge, is often related to severity of
disability, and may therefore influence clinical decision-
making.
After fitting the model, registrants were ranked according to
their propensity score and categorized into quintiles; 5 strata
are recommended to remove approximately 90% of bias
Figure 1 Flow diagram of patient exclusions
AuSCR = Australian Stroke Clinical Registry.
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resulting from certain types of patients being preferentially
allocated to certain treatments.21,24 Data were then analyzed
within strata rather than matching on the propensity score.
This method was chosen as it enabled us to retain almost all of
our sample, thereby maximizing the external validity of our
results, an important feature of clinical registries.24 Each
stratum was assessed for balance in baseline characteristics
between treated and untreated groups based on standardized
differences in the mean or prevalence.25,26 An SD of <0.1
indicated a negligible difference between those who were and
were not prescribed antihypertensive medication at discharge,
i.e., optimal matching for that covariate.19
Multivariable competing-risk regression, in which deaths due
to non-CVD causes were the competing risk, was used to
assess the association between prescription of antihyperten-
sive medications at discharge and deaths due to CVD.
Competing-risks regression enabled us to account for po-
tential bias due to death from non-CVD causes. The statistical
analysis was undertaken with STATA IC version 12. The
assumptions for this model are as per Fine and Gray,15
a semiparametric, subdistribution model. Postestimation tests
to confirm assumptions of proportionality were undertaken.
Graphically, the Schoenfeld residuals appeared to be relatively
constant over time (figure e-1, links.lww.com/WNL/A191),
with a significance of p = 0.0204, which was considered ac-
ceptable given our large sample size. For comparison, a Cox
proportional hazard regression was also conducted for death
from any cause. Models were run separately for each pro-
pensity score quintile. An overall model, using bootstrap
standard errors to account for the variability in estimation,26
was also run in which the propensity score from each in-
dividual quintile was included as a covariate in the model. The
overall regression analyses were repeated excluding strata with
poor balance on baseline differences based on SDs. All models
were adjusted for patient clustering by hospital.
Standard protocol approvals, registrations,
and patient consents
Hospitals participating in the registry are required to obtain
ethics approval before commencing data collection. To min-
imize selection bias, an opt-out method of consent is used.
Table 1 Baseline characteristics by prescription of
antihypertensive medications at discharge prior
to stratification by propensity score
Prescribed antihypertensive
medication at discharge, n (%)
p Value
No,
n = 3,616
Yes,
n = 8,582
Received care in
a stroke unit
2,728 (75) 7,168 (84) <0.001
Age, ya
<65 1,351 (38) 1,944 (23)
65–74 760 (21) 2,161 (25) <0.001
75–84 867 (24) 2,790 (33)
85+ 608 (17) 1,626 (19)
Femalea 1,623 (45) 3,819 (45) 0.7
Able to walk on
admission (stroke
severity measure)b
1,688 (54) 3,803 (48) <0.001
Stroke typea
Intracerebral
hemorrhage
391 (11) 782 (9)
Ischemic 2,156 (60) 5,725 (67) <0.001
TIA 886 (25) 1,852 (22)
Unknown cause 169 (5) 221 (3)
Index of relative
socioeconomic
advantage and
disadvantagec
Quintile 1 674 (19) 1,459 (17)
Quintile 2 530 (15) 1,490 (17)
Quintile 3 550 (15) 1,419 (17) <0.001
Quintile 4 651 (18) 1,705 (20)
Quintile 5 1,211 (33) 2,509 (29)
Transfer 435 (12) 821 (10) <0.001
Discharge
destination
Home 2,448 (68) 4,927 (57)
Rehabilitation 858 (24) 3,122 (36) <0.001
Residential care 310 (9) 533 (6)
Year of admission
2009 129 (4) 432 (5)
2010 325 (9) 1,087 (13)
2011 510 (14) 1,413 (16) <0.001
2012 1,234 (34) 1,987 (23)
2013 1,418 (39) 3,663 (43)
Table 1 Baseline characteristics by prescription of
antihypertensivemedications at discharge prior to
stratification by propensity score (continued)
Prescribed antihypertensive
medication at discharge, n (%)
p Value
No,
n = 3,616
Yes,
n = 8,582
Previous stroke 644 (18) 1,714 (20) 0.006
Interpreter required 144 (4) 405 (5) 0.07
a Missing data (<1%).
b Missing data (9%).
c Lower quintiles indicate a greater level of social disadvantage.
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The annual opt-out rate for acute demographic and clinical
data for the study period was <3% each year.27 Additional
ethics approval was also obtained from the Australian Institute
of Health and Welfare to allow linkage with the NDI.
Results
A total of 12,198 patients from 40 hospitals were included.
The proportion prescribed antihypertensive medication at
discharge was 70%, with large variations between hospitals
(range 44%–89%; see figure e-2, links.lww.com/WNL/
A191). Among this cohort, 45% were female, 65% had ex-
perienced an ischemic stroke, and the median age was 74
years. Most (60%) were discharged directly to home, 33% to
rehabilitation, and 7% to residential care. The median length
of stay was 7 days for those with an ICH, 6 days for those with
ischemic stroke, and 2 days for those with TIA.
All the variables included in the calculation of our propensity
score were associated either with prescription of antihyper-
tensive medications at discharge or with death due to CVD at
180 days after their admission or both (table 1). Older
patients (aged >65 years), those treated in a stroke unit, and
those with greater socioeconomic advantage were more likely
to be prescribed antihypertensive medications at discharge. At
180 days following their acute hospital admission, 785
patients who survived their hospitalization had died (7%) and
521 (66%) of these deaths were due to CVD. Other common
causes of death were neoplasms (15%), endocrine and met-
abolic disorders (6%), and respiratory disorders (4%).
Propensity scores, based on the odds of being discharged on
antihypertensive medication, were able to be generated for
10,984 (90%) eligible registrants. The fit of the model used to
derive the propensity score had acceptable discrimination
(area under the receiver operating curve of 0.7) and calibra-
tion (Hosmer-Lemeshow test χ = 4,713, p = 0.13). The mean
variance inflation factor was acceptable at 1.12 (range 1.02,
1.28). The distribution of the propensity scores for the full
sample and the sample excluding quintile 1 is displayed in
figure e-3 (links.lww.com/WNL/A191). Following stratifi-
cation by propensity scores, those who were and were not
prescribed antihypertensive medication at discharge were
well-matched within quintiles 2 and 3 (i.e., negligible differ-
ence, SD < 0.1) for all covariates used to estimate the pro-
pensity score. There were small differences in the SD for some
covariates (SD 0.1–0.16) for the other strata, with the greatest
heterogeneity being observed in quintile 1 (imbalance in 4 of
the 11 variables included in the propensity score de-
velopment) (table e-2, links.lww.com/WNL/A192).
For the strata in which all covariates were balanced, there was
a 36%–37% reduction in the subhazard of death due to CVD
at 180 days following stroke admission (quintile 2 subhazard
ratio [SHR] 0.64, 95% confidence interval [CI] 0.43–0.97 and
quintile 3 SHR 0.63, 95% CI 0.46–0.86) (table 2, figure 2). In
the overall model, excluding quintile 1, there was a 23% re-
duction in the subhazard of death due to CVD associated with
the prescription of antihypertensive medication (SHR 0.77,
95% CI 0.61–0.97). Similar results were found for the out-
come of all-cause death, where covariates were balanced be-
tween groups (table 2; figures 2 and 3). In a sensitivity
analysis, analogous results were found when we ran our
analyses including patients with a documented date but
missing cause of death (n = 94, 11%) re-classified as having
(1) a CVD or (2) a non-CVD cause of death (table e-3, links.
lww.com/WNL/A192).
Discussion
The major finding from this large observational study is that
prescription of antihypertensive medications at discharge
from acute care following stroke or TIA was associated with
improved survival at 180 days after admission. This finding
was robust and clinically relevant irrespective of the outcome
assessed (death due to CVD or all-cause deaths). The dif-
ference in outcomes between those prescribed and not pre-
scribed antihypertensive medications was greatest for
propensity score quintiles in which there was balance between
the groups in covariates used to develop the score (i.e., the
strata with the least chance that the effect of prescription of
antihypertensive medication would be confounded).
The context of our findings is different from those from
clinical trials in this area. We specifically investigated whether
patients were prescribed a blood pressure–lowering medica-
tion at discharge. Patients in our observational study did not
necessarily commence or restart blood pressure–lowering
therapy in the first few days following stroke. In clinical trials,
such as the Scandinavian Candesartan Acute Stroke Trial,5
where outcomes were poorer in people on blood pressure–
lowering therapy than those who were not, all patients com-
menced therapy during hospitalization and sometimes on the
same day as the stroke.
Findings from our study are critical to understanding the
benefits of clinician prescription of antihypertensive medi-
cations as part of discharge planning in acute stroke care.
Prescribing these medications in the acute hospital setting has
been shown to be associated with long-term adherence to
medications,28 improved long-term control of blood pres-
sure,29 and continued prescription.30 It may be that medi-
cations prescribed within this setting are perceived as being
more important by the patient, leading to better adherence.
Furthermore, once the patient is in the community, patients
may not be prescribed antihypertensive medications due to
lapses in continuity of care. Up to a quarter of patients do not
have an appointment with a doctor within 3 months of their
stroke.31,32
We did not achieve balance in clinical and demographic
characteristics within all propensity score quintiles. These
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differences are caused by patients in the dataset with outlying
characteristics. Patients in the propensity score strata with the
greatest imbalance of covariates (quintile 1) had the greatest
proportion of patients aged <65 years. This group is likely to
have better survival outcomes compared to their older
counterparts, regardless of their management. This may have
influenced the outcomes observed in quintile 1 (table e-2,
links.lww.com/WNL/A192).
Not having a measure of blood pressure in the dataset is
a limitation and means that patients who were not provided
antihypertensive therapy due to contraindications such as low
blood pressure were included in these analyses. Another
common reason for not prescribing antihypertensive medi-
cation is the associated greater risk of falls in the elderly.33,34
There is also recent evidence from community-based studies
or post hoc analyses of clinical trial data that low blood
pressure is associated with poor outcomes in survivors of
stroke.35−37 The inability to account for these contra-
indications would underestimate the risk differences between
patients prescribed and not prescribed antihypertensive
medications. However, only about 3% of patients with stroke
have a contraindication to antihypertensive therapy.
We additionally adjusted for potential sources of unmeasured
confounding through stratification by propensity score and
Table 2 Effect of prescription of antihypertensive medication at discharge on death due to cardiovascular disease (CVD)
at 180 days after hospital admission by quintiles based on propensity scores and overall
Propensity score
Alive 180
days,
n (%)
Died
(CVD),
n (%)
Died (non-
CVD),
n (%)
CVD death within
180 days,
subhazard
ratio (95% CI)
Death within
180 days,
hazard
ratio (95% CI)
Median
(range) n
Full sample unadjusted
Antihypertensives NA 8,582 517 (6) 351 (4) 166 (2) 0.86 (0.67, 1.11) 0.80 (0.69, 0.94)
No antihypertensives NA 3,616 268 (7) 170 (5) 97 (3)
Quintile 1
Antihypertensives 0.56 (0.30, 0.62) 1,177 1,115 (95) 39 (3) 23 (2) 1.3 (0.6, 2.8) 0.92 (0.62, 1.35)
No antihypertensives 0.54 (0.26, 0.62) 1,021 963 (94) 26 (3) 32 (3)
Quintile 2
Antihypertensives 0.67 (0.62, 0.70) 1,442 1,356 (94) 64 (4) 22 (2) 0.64 (0.43, 0.97) 0.69 (0.46, 1.02)
No antihypertensives 0.66 (0.62, 0.70) 755 691 (92) 51 (7) 13 (2)
Quintile 3
Antihypertensives 0.74 (0.70, 0.77) 1,644 1,541 (94) 75 (5) 28 (2) 0.63 (0.46, 0.86) 0.61 (0.44, 0.85)
No antihypertensives 0.74 (0.70, 0.77) 552 497 (90) 39 (7) 16 (3)
Quintile 4
Antihypertensives 0.80 (0.77, 0.82) 1,745 1,649 (95) 61 (4) 35 (2) 0.99 (0.58, 1.67) 1.08 (0.75, 1.57)
No antihypertensives 0.79 (0.77, 0.82) 453 430 (95) 16 (4) 7 (2)
Quintile 5
Antihypertensives 0.85 (0.82, 0.91) 1,862 1,727 (93) 92 (5) 43 (3) 1.3 (0.72, 2.24) 0.80 (0.55, 1.15)
No antihypertensives 0.85 (0.82, 0.91) 333 303 (91) 13 (4) 17 (5)
Overall excluding quintile 1
Antihypertensives 0.78 (0.62, 0.91) 6,693 6,950 (94) 312 (4) 143 (2) 0.77 (0.61, 0.97) 0.74 (0.64, 0.87)
No antihypertensives 0.74 (0.62, 0.91) 2,093 2,385 (92) 144 (6) 65 (3)
Overall
Antihypertensives 0.75 (0.67, 0.82) 7,870 7,388 (94) 331 (4) 151 (2) 0.84 (0.64, 1.11) 0.78 (0.65, 0.92)
No antihypertensives 0.67 (0.58, 0.77) 3,114 2,884 (93) 145 (5) 85 (3)
Abbreviation: CI = confidence interval.
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exclusion of those in the poorly matched stratum. Exclusion of
the poorly matched stratum increased the internal validity of
our findings at the expense of external validity (generalizabil-
ity). As is common with registry datasets, our analyses were
limited to variables routinely collected in the registry. This
limited the scope of our analyses and our ability to account for
all possible confounding factors, such as comorbidities, in our
analyses. It is unlikely that this would greatly affect our findings.
In yet to be published work by the authors, the addition of
a comorbidity index derived from patient-level administrative
data and merged with the AuSCR data increased the predictive
ability of the registry only model for survival by <1%.
Another limitation was missing cause of death for a small
number of patients. However, including these missing data in
sensitivity analyses resulted in no change in the primary in-
terpretation of our results. We also do not know whether
patients utilized the medications they were prescribed at
discharge from hospital or whether some patients were pre-
scribed medications after discharge. However, these scenarios
would have biased our results towards the null and led to
a possible underestimation of our effect sizes. In future work,
the AuSCR data will be linked to the Australian Pharmaceu-
tical Benefits Schedule database to provide more robust data
with regards to adherence and persistence with these medi-
cations. Patients with mild stroke or TIA who were not ad-
mitted to hospital and managed entirely in ambulatory
services would not have been captured in our study. Thus, our
results pertain to patients admitted to hospital. Finally, the
number of outcomes in the cohort was not large enough to
Figure 2 Cumulative subhazard of death due to cardiovascular disease
Including only patients within propensity score quin-
tiles with acceptable levels of balance in covariates
between groups (n = 8,786). Subhazards derived from
semiparametric competing risks regression. Solid
line: not prescribed antihypertensive medication;
dotted line: prescribed antihypertensive medication.
Figure 3 Cumulative hazard of death
Including only patients within propensity score quin-
tiles with acceptable levels of balance in covariates
between groups (n = 8,786). Hazards derived from
semiparametric Cox proportional hazards regression.
Solid line: not prescribed antihypertensive medication;
dotted line: prescribed antihypertensive medication.
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permit subgroup analyses such as stratification by age groups
or type of stroke.
There remains uncertainty regarding the optimal timing to
prescribe antihypertensive medications after a stroke. Due to
the indisputable benefit of lowering blood pressure, ethical
approval to conduct clinical trials to unequivocally answer this
question is challenging. Using appropriate statistical techni-
ques and a real-world sample of patients with stroke and TIA,
we provide evidence that can be used to support the provision
of antihypertensive medications at discharge from hospital
after stroke, as is common practice in Australia and other
countries.
Author contributions
N.E.A.: drafting of the manuscript, literature review, analysis
of data, interpretation of the data. J.K.: drafting of the man-
uscript, literature review, analysis of data, interpretation of the
data. A.G.T.: drafting of the manuscript, conceptualization
and design of the study, revisions and interpretation of the
data. M.F.K.: drafting of the manuscript, contribution to data
analysis methods, revisions and interpretation of the data.
N.A.L.: conceptualization and design of the study, revisions
and interpretation of the data. C.S.A.: conceptualization and
design of the study, revisions and interpretation of the data.
G.A.D.: conceptualization and design of the study, revisions
and interpretation of the data. K.H.: conceptualization and
design of the study, revisions and interpretation of the data.
S.M.: conceptualization and design of the study, revisions and
interpretation of the data. C.L.: conceptualization and design
of the study, revisions and, interpretation of the data. S.F.:
conceptualization and design of the study, revisions and in-
terpretation of the data. R.G.: conceptualization and design of
the study, revisions and interpretation of the data. N.G.: ac-
quisition of data, revisions and interpretation of the data. R.G.:
acquisition of data, revisions and interpretation of the data.
S.E.: acquisition of data, revisions and interpretation of the
data. D.A.C.: conceptualization and design of the study, su-
pervision of analyses, interpretation of the data.
Acknowledgment
The authors thank the members of the AuSCR Steering
Committee and staff from The George Institute for Global
Health and the Florey Institute of Neuroscience and Mental
Health whomanage the AuSCR, particularly Joyce Lim, Kasey
Wallis, Enna Salama, Kate Paice, Francis Kung, Sam Shehata,
and Karen Moss; Megan Reyneke and Doreen Busingye for
assisting with data coding and literature search; and the
hospital clinicians and patients who contribute data to
AuSCR.
Study funding
The AuSCR was supported by grants from the NHMRC
(1034415), Monash University, Queensland Health, Victo-
rian Department of Health and Human Services, the Stroke
Foundation, Allergan Australia, Ipsen, Boehringer Ingelheim,
and consumer donations. The following authors receive
Research Fellowship support from the National Health and
Medical Research Council: Dominique Cadilhac (1063761
co-funded Heart Foundation); Nadine Andrew (1072053);
Craig Anderson (1081356); Chris Levi (1043913); Natasha
Lannin (1112158); Amanda Thrift (1042600); Monique
Kilkenny (1109426).
Disclosure
N. Andrew and J. Kim report no disclosures relevant to the
manuscript. A. Thrift: board member, Stroke Foundation.
M. Kilkenny reports no disclosures relevant to the manu-
script. N. Lannin: restricted educational grants from Allergan
Australia (2009, 2010) and Ipsen (2010) awarded to the
Management Committee of the Australian Stroke Clinical
Registry (AuSCR) to improve aspects of the data tool.
C. Anderson: as per N. Lannin regarding industry support for
AuSCR. G. Donnan: as per N. Lannin regarding industry
support for AuSCR. K. Hill reports no disclosures relevant to
the manuscript. S. Middleton: member, Clinical Council,
Stroke Foundation. C. Levi: as per N. Lannin regarding in-
dustry support for AuSCR. Member, Clinical Council, Stroke
Foundation. S. Faux: as per N. Lannin regarding industry
support for AuSCR. R. Grimley, N. Gange, R. Geraghty, and
S. Ermel report no disclosures relevant to the manuscript.
D. Cadilhac: restricted educational grants from Allergan
Australia (2009, 2010), Ipsen (2010), and Boehringer (2013)
awarded to the Management Committee of the AuSCR to
improve aspects of the data tool or as contributions to sup-
porting an annual national workshop; data custodian for the
AuSCR. Go to Neurology.org/N for full disclosures.
Received June 1, 2017. Accepted in final form November 27, 2017.
References
1. Lakhan S, Sapko M. Blood pressure lowering treatment for preventing stroke re-
currence: a systematic review and meta-analysis. Int Arch Med 2009;2:30.
2. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of
cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;
387:957–967.
3. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in
patients with stroke or transient ischemic attack: a guideline for healthcare pro-
fessionals from the American Heart Association/American Stroke Association. Stroke
2011;42:227–276.
4. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-
pressure-lowering regimen among 6,105 individuals with previous stroke or transient
ischaemic attack. Lancet 2001;358:1033–1041.
5. Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan
for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-
blind trial. Lancet 2011;377:741–750.
6. Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertensive treatment after
acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative
Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet
Neurol 2010;9:767–775.
7. The ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing
antihypertensive treatment, for management of high blood pressure in acute stroke
(ENOS): a partial-factorial randomised controlled trial. Lancet 2015;385:617–628.
8. Carcel C, Anderson CS. Timing of blood pressure lowering in acute ischemic stroke.
Curr Atheroscler Rep 2015;17:1–8.
9. Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early
ischemic stroke: meta-analysis. Stroke 2015;46:1883–1889.
10. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients
with acute intracerebral hemorrhage. N Engl J Med 2013;368:2355–2365.
11. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in
patients with stroke and transient ischemic attack: a guideline for healthcare pro-
fessionals from the American Heart Association/American Stroke Association. Stroke
2014;45:2160–2236.
12. Kleinig T. Antihypertensive treatment should be commenced in hospital after stroke:
Pro. Int J Stroke 2016;12:121–122.
e752 Neurology | Volume 90, Number 9 | February 27, 2018 Neurology.org/N
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
13. Phan T. Blood pressure-lowering therapy post stroke should be commenced before
discharge from hospital: Contra. Int J Stroke 2016;12:119–120.
14. National Stroke Foundation. National Stroke Audit: Acute Services Clinical Audit
Report 2015. Melbourne, Australia: 2015. Available at: informme.org.au/en/stroke-
data/Acute-audits. Accessed February 2017.
15. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing
risk. J Am Stat Assoc 1999;94:496–509.
16. Reeves MJ, Wehner S, Organek N, et al. Accuracy of identifying acute stroke
admissions in a Michigan Stroke Registry. Prev Chronic Dis 2011;8:A62.
17. Cadilhac DA, Kim J, Lannin NA, et al. National stroke registries for monitoring and
improving the quality of hospital care: a systematic review. Int J Stroke 2016;11:28–40.
18. Australian Bureau of Statistics. Socio-economic Indexes for Areas (SEIFA) 2011. Available
at: abs.gov.au/websitedbs/censushome.nsf/home/seifa. Accessed January 2017.
19. Austin PC. An introduction to propensity score methods for reducing the effects of
confounding in observational studies. Multivariate Behav Res 2011;46:399–424.
20. Martens EP, de Boer A, Pestman WR, Belitser SV, Stricker BH, Klungel OH. Com-
paring treatment effects after adjustment with multivariable Cox proportional hazards
regression and propensity score methods. Pharmacoepidemiol Drug Saf 2008;17:1–8.
21. Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification
on the propensity score. J Am Stat Assoc 1984;79:516–524.
22. Counsell C, Dennis M, McDowall M, Warlow C. Predicting outcome after acute and
subacute stroke: development and validation of new prognostic models. Stroke 2002;
33:1041–1047.
23. Cadilhac DA, Kilkenny MF, Levi CR, et al. Risk-adjusted hospital mortality rates for
stroke: evidence from the Australian Stroke clinical registry (AuSCR). Med J Aust
2017;206:345–350.
24. D’Agostino RB Jr. Propensity scores in cardiovascular research. Circulation 2007;115:
2340–2343.
25. Austin PC. Assessing balance in measured baseline covariates when using many-to-
one matching on the propensity-score. Pharmacoepidemiol Drug Saf 2008;17:
1218–1225.
26. Austin PC. Propensity-score matching in the cardiovascular surgery literature from
2004 to 2006: a systematic review and suggestions for improvement. J Thorac Car-
diovasc Surg 2007;134:1128–1135.
27. Cadilhac D, Lannin N, Anderson C, et al. Protocol and pilot data for establishing the
Australian Stroke Clinical Registry (AuSCR). Int J Stroke 2010:217–226.
28. Tsai JP, Rochon PA, Raptis S, Bronskill SE, Bell CM, Saposnik G. A prescription at
discharge improves long-term adherence for secondary stroke prevention. J Stroke
Cerebrovasc Dis 2014;23:2308–2315.
29. Touze´ E, Coste J, Voicu M, et al. Implementation of Prevention After a Cerebrovas-
cular Event (IMPACT) study. Stroke 2008;39:1834–1843.
30. Thrift AG, Kim J, Douzmanian V, et al. Discharge is a critical time to influence 10-year
use of secondary prevention therapies for stroke. Stroke 2014;45:539–544.
31. Redfern J, McKevitt C, Rudd AG, Wolfe CD. Health care follow-up after stroke:
opportunities for secondary prevention. Fam Pract 2002;19:378–382.
32. Ullberg T, Zia E, Petersson J, Norrving B. Doctor’s follow-up after stroke in the south
of Sweden: an observational study from the Swedish stroke register (Riksstroke). Eur
Stroke J 2016;1:114–121.
33. Callisaya ML, Sharman JE, Close J, Lord SR, Srikanth VK. Greater daily defined dose
of antihypertensive medication increases the risk of falls in older people: a population-
based study. J Am Geriatr Soc 2014;62:1527–1533.
34. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip
fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med 2012;
172:1739–1744.
35. Kaplan RC, Tirschwell DL, Longstreth WT Jr, et al. Blood pressure level and out-
comes in adults aged 65 and older with prior ischemic stroke. J Am Geriatr Soc 2006;
54:1309–1316.
36. Ovbiagele B, Diener HC, Yusuf S, et al. Level of systolic blood pressure within the
normal range and risk of recurrent stroke. JAMA 2011;306:2137–2144.
37. Kim J, Gall SL, Nelson MR, Sharman JE, Thrift AG. Lower systolic blood pressure is
associated with poorer survival in long-term survivors of stroke. J Hypertens 2014;32:
904–911.
Neurology.org/N Neurology | Volume 90, Number 9 | February 27, 2018 e753
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
FULL-LENGTH ARTICLE NPub.org/ej3vt4
Prescription of antihypertensive medication at
discharge influences survival following stroke
Nadine E. Andrew, PhD, Joosup Kim, PhD, Amanda G. Thrift, PhD, Monique F. Kilkenny, PhD,
Natasha A. Lannin, PhD, Craig S. Anderson, PhD, Geoffrey A. Donnan, MD, Kelvin Hill, B.AppSci,
Sandy Middleton, PhD, Christopher Levi, MBBS, Steven Faux, FAFRM (RACP), Rohan Grimley, MBBS,
Nisal Gange, MBBS, Richard Geraghty, MBBS, Sharan Ermel, BN(Hons), and Dominique A. Cadilhac, PhD,
On behalf of the Australian Stroke Clinical Registry Consortium
Cite as: Neurology® 2018;90:e745-e753. doi:10.1212/WNL.0000000000005023
Correspondence
Prof. Cadilhac
dominique.cadilhac@
monash.edu
Study question
How do antihypertensive medication prescriptions influence
the risk of cardiovascular death in patients who have survived
strokes or TIAs?
Summary answer
Cardiovascular and all-cause mortality rates are lower for
patients who are prescribed antihypertensive drugs at dis-
charge than for those who are not.
What is known and what this paper adds
The American Heart Association recommends that patients
who survive a stroke be prescribed antihypertensive drugs, but
some studies have questioned the benefits in patients with
ischemic stroke. This study, conducted in Australia, provides
evidence for the utility of antihypertensive drugs for patients
who survive strokes or TIAs.
Participants and setting
The authors examined 12,198 patients who were enrolled in
the Australian Stroke Clinical Registry (AuSCR) between 2009
and 2013 and discharged to the community or rehabilitation.
Design, size, and duration
The authors retrospectively accessed the AuSCR for clinical
and outcome data including antihypertensive prescriptions at
discharge from acute care hospitals. Propensity scores were
calculated based on various factors associated with antihyper-
tensive prescriptions, and on death at 180 days. These scores
were used to stratify patients into propensity score quintiles for
multivariable competing-risks regression with cardiovascular
death as a competing risk.
Primary outcomes
The primary outcome was cardiovascular death within 180
days of hospital admission.
Main results and the role of chance
Of the patients, 70% were prescribed antihypertensive drugs
at discharge from 40 hospitals, and 785 (7%) died within
180 days of admission. Of those deaths, 521 (66%) were from
cardiovascular events. The authors successfully calculated
propensity scores for 10,984 (90%) patients. A multivariable
regressionmodel excluding the lowest propensity score quintile
(due to its high heterogeneity) showed that antihypertensive
drug prescriptions were associated with a 26% reduction in the
risk of all-cause death (hazard ratio, 0.74; 95% CI, 0.64–0.87)
and a 23% reduction in the risk of cardiovascular death (sub-
hazard ratio, 0.77; 95% CI, 0.61–0.97).
Bias, confounding, and other reasons for caution
Contraindications against antihypertensive drug prescription
could not be taken into account, and the cause of death was
unknown for some patients.
Generalizability to other populations
A subgroup that had poor matching of characteristics
(i.e., those in the lowest propensity quintile) between treated
and untreated patients were excluded. This subgroup had the
greatest proportion of patients aged less than 65 years. This
may limit generalizability to relatively young patients.
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